Bert Lum
Overview
Explore the profile of Bert Lum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
529
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reyner E, Lum B, Jing J, Kagedal M, Ware J, Dickmann L
Clin Transl Sci
. 2019 Nov;
13(2):410-418.
PMID: 31729137
Pharmacokinetic (PK) variability in cancer clinical trials may be due to heterogeneous populations and identifying sources of variability is important. Use of healthy subjects in clinical pharmacology studies together with...
2.
Quartino A, Li H, Kirschbrown W, Mangat R, Wada D, Garg A, et al.
Cancer Chemother Pharmacol
. 2018 Nov;
83(2):329-340.
PMID: 30467591
Purpose: The aim of the study was to characterize the population pharmacokinetics (PK) of the intravenous formulation of trastuzumab, assess the impact of patient and pathological covariates on trastuzumab PK,...
3.
Garg A, Quartino A, Li J, Jin J, Wada D, Li H, et al.
Cancer Chemother Pharmacol
. 2014 Aug;
74(4):819-29.
PMID: 25119184
Purpose: To characterize the population pharmacokinetics (PK) of pertuzumab across clinical trials in a variety of solid tumors, evaluate the potential impact of patient characteristics on PK, and confirm the...
4.
Garg A, Li J, Clark E, Knott A, Carrothers T, Marier J, et al.
Cancer Chemother Pharmacol
. 2013 Sep;
72(5):1133-41.
PMID: 23999693
Purpose: The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel for first-line treatment of HER2-positive metastatic breast cancer included a substudy to determine...
5.
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim S, et al.
Lancet Oncol
. 2012 Aug;
13(9):869-78.
PMID: 22884505
Background: A subcutaneous formulation of trastuzumab has been developed, offering potential improvements in patient convenience and resource use compared with the standard intravenous infusion of the drug. We compared the...
6.
Denlinger C, Blanchard R, Xu L, Bernaards C, Litwin S, Spittle C, et al.
Cancer Chemother Pharmacol
. 2009 May;
65(1):97-105.
PMID: 19415281
Purpose: The purpose of this study was to evaluate the effect of bevacizumab on the pharmacokinetics (PK) of irinotecan and its active metabolite. Exploratory analyses of the impact of variability...
7.
Lu J, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J
Cancer Chemother Pharmacol
. 2008 Jan;
62(5):779-86.
PMID: 18205003
Objective: To characterize the population pharmacokinetics of bevacizumab and the influence of demographic factors, disease severity, and concomitantly used chemotherapy agents on it's pharmacokinetic behavior. Patients And Methods: Data from...
8.
Ng C, Xiao Y, Putnam W, Lum B, Tropsha A
J Pharm Sci
. 2004 Sep;
93(10):2535-44.
PMID: 15349962
We have developed quantitative structure-pharmacokinetic parameters relationship (QSPKR) models using k-nearest-neighbor (k-NN) and partial least-square (PLS) methods to predict the volume of distribution at steady state (Vss) and clearance (CL)...
9.
Reid T, Valone F, LiPera W, Irwin D, Paroly W, Natale R, et al.
Lung Cancer
. 2004 Aug;
45(3):381-6.
PMID: 15301879
This multicenter phase II trial evaluated the therapeutic activity and safety profile of pivaloyloxymethyl butyrate (Pivanex, AN-9) as a single agent in refractory non-small cell lung cancer (NSCLC). Pivanex (2.34...
10.
Greenberg P, Lee S, Advani R, Tallman M, Sikic B, Letendre L, et al.
J Clin Oncol
. 2004 Mar;
22(6):1078-86.
PMID: 15020609
Purpose: To determine whether adding the multidrug resistance gene-1 (MDR-1) modulator valspodar (PSC 833; Novartis Pharmaceuticals, Hanover, NJ) to chemotherapy provided clinical benefit to patients with poor-risk acute myeloid leukemia...